CHRS / Coherus Oncology, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Amendment No. 1 to Coherus Oncology, Inc. 2014 Employee Stock Purchase Plan.

EXHIBIT 10.4 AMENDMENT NO. 1 TO COHERUS ONCOLOGY, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN This Amendment No. 1 (this “Amendment”) to the 2014 Employee Stock Purchase Plan (the “Plan”) of Coherus Oncology, Inc., a Delaware corporation (the “Company”) is made pursuant to Section 7.5 of the Plan, effective as of April 23, 2025. WITNESSETH THAT: WHEREAS, the Company presently maintains the Plan for the

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update – LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending c

Exhibit 99.1 Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update – LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and marketable securities of $238 million – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif

Coherus Oncology, Inc. Amended and Restated 2014 Equity Incentive Award Plan.

EXHIBIT 10.2 COHERUS ONCOLOGY, INC. AMENDED AND RESTATED 2014 EQUITY INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE The purpose of the Coherus Oncology, Inc. Amended and Restated 2014 Equity Incentive Award Plan (as it may be amended from time to time, the “Plan”) is to promote the success and enhance the value of Coherus Oncology, Inc. (the “Company”) by linking the individual interests of the members o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coheru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 COHERUS ONCOLOGY,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 COHERUS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission F

Coherus Oncology, Inc. 2014 Employee Stock Purchase Plan.

Exhibit 10.3 COHERUS ONCOLOGY, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE, SCOPE AND ADMINISTRATION OF THE PLAN 1.1 Purpose and Scope. The purpose of the Coherus Oncology, Inc. 2014 Employee Stock Purchase Plan, as it may be amended from time to time, (the “Plan”) is to assist employees of Coherus Oncology, Inc., a Delaware corporation, (the “Company”) and its Designated Subsidiarie

Coherus Oncology, Inc. 2016 Employment Commencement Incentive Plan.

Exhibit 10.5 COHERUS ONCOLOGY, INC. 2016 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN ARTICLE 1. PURPOSE The purpose of the Coherus Oncology, Inc. 2016 Employment Commencement Incentive Plan (as it may be amended from time to time, the “Plan”) is to promote the success and enhance the value of Coherus Oncology, Inc. (the “Company”) by linking the individual interests of the Eligible Individuals to those

Executive Change in Control and Severance Plan, effective January 1, 2023.

EXHIBIT 10.6 COHERUS ONCOLOGY, INC. EXECUTIVE CHANGE IN CONTROL AND SEVERANCE PLAN (AND SUMMARY PLAN DESCRIPTION) EFFECTIVE JANUARY 1, 2023 This Coherus Oncology, Inc. Executive Change in Control and Severance Plan (this “Plan”) was originally established effective as of April 5, 2017 and is hereby amended and restated effective January 1, 2023 (the “Effective Date”). The purpose of this Plan is t

Letter Agreement between Coherus BioSciences, Inc. and Paul Reider, dated as of May 8, 2025

EXHIBIT 10.1 [***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. May 8, 2025 Paul Reider [***] [***] Dear Paul, Your position as Chief Commercial Officer will end by mutual agreement effective April 30, 2025 (the “Separation Date”). This letter (the “Agreement”) provides information regarding the mutual separation pack

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 COHERUS ONCOLOGY, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2025 COHERUS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 COHERUS ONCOLOGY, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 COHERUS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission Fi

Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics

EXHIBIT 99.1 Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics REDWOOD CITY, Calif., May 30, 2025 (GLOBE NEWSWIRE) - Coherus Oncology, Inc. (Coherus Oncology, Nasdaq: CHRS), a commercial-stage innovative oncology company, formerly named Coherus BioSciences Inc., announced its name change today, to better align with its exclusive

Second Amended and Restated Bylaws of Coherus Oncology, Inc., effective as of May 29, 2025.

EXHIBIT 3.2 AMENDED AND RESTATED BYLAWS OF COHERUS ONCOLOGY, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES FOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 COHERUS ONCOLOGY, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 COHERUS ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission Fil

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Coherus BioSciences, Inc., effective as of May 29, 2025

EXHIBIT 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF COHERUS BIOSCIENCES, INC. Coherus BioSciences, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Delaware General Corporation Law”), hereby certifies as follows: 1.The name of this corporation is Coherus BioSciences, Inc., and the original Certifica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 COHERUS BIOSCIENCES, INC. (Name of Subject Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO/A (Amendment No. 1) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 COHERUS BIOSCIENCES, INC. (Name of Subject Company and Filing Person (Issuer)) 1.500% Convertible Senior Subordinated Notes due 2026 (Title of Class of Securities) 19249HAB9 (CUSIP Number of Class of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coher

Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update – Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patie

Exhibit 99.1 Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update – Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 COHERUS BIOSCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 COHERUS BIOSCIENCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2025 COHERUS BIOSCIENCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2025 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commissio

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Schedule TO (Form Type) Coherus BioSciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 COHERUS BIOSCIENCES, INC. (Name of Subject Company and Filing Person

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 COHERUS BIOSCIENCES, INC. (Name of Subject Company and Filing Person (Issuer)) 1.500% Convertible Senior Subordinated Notes due 2026 (Title of Class of Securities) 19249HAB9 (CUSIP Number of Class of Securities) Coherus

Fundamental Change Notice and Offer to Repurchase to Holders of 1.500% Convertible Senior Subordinated Notes due 2026, dated April 16, 2025.

TABLE OF CONTENTS  Exhibit (a)(1)(A) COHERUS BIOSCIENCES, INC. FUNDAMENTAL CHANGE NOTICE AND OFFER TO REPURCHASE FOR CASH ANY AND ALL OUTSTANDING CONVERTIBLE SENIOR SUBORDINATED NOTES DUE 2026 (CUSIP / ISIN No. 19249H AB9 / US19249HAB96)   The Tender Offer (as defined below) will expire at 5:00 p.m., New York City time, on May 14, 2025, subject to extension as described in herein (such date and ti

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

EXHIBIT 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introductory Note On December 2, 2024, Coherus BioSciences, Inc., a Delaware corporation (“Coherus”), entered into an Asset Purchase Agreement (the “UDENYCA Purchase Agreement”) by and between Coherus and Intas Pharmaceuticals Ltd., a limited company incorporated in India (“Purchaser” or “Intas”). Pursuant to the UDENYCA Pur

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise – $250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key data catalysts – – Coherus to f

EXHIBIT 99.1 Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise – $250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key data catalysts – – Coherus to focus exclusively on its innovative novel oncology programs including: – LOQTORZI®, a revenue-generating and differentiated PD-1 inhibitor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2025 COHERUS BIOSCIENCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2025 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 COHERUS BIOSCIENCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commissio

Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes – Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture –

EXHIBIT 99.1 Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes – Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture – REDWOOD CITY, Calif., April 1, 2025 - Coherus BioSciences, Inc. (“Coherus” or the “Company,” NASDAQ: CHRS) announced today that it has entered into privately negotiated transactions (the “

First Supplemental Indenture, dated March 31, 2025, between Coherus BioSciences, Inc. and U.S. Bank Trust Company, National Association, as trustee.

EXHIBIT 4.1 Execution Version FIRST SUPPLEMENTAL INDENTURE THIS FIRST SUPPLEMENTAL INDENTURE, dated as of March 31, 2025 (this “Supplemental Indenture”), is by and among Coherus BioSciences, Inc., a Delaware corporation (the “Company”), and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as trustee (the “Trustee”). WITNESSETH WHEREAS, the

Subsidiaries of Coherus BioSciences, Inc.

EXHIBIT 21.1 SIGNIFICANT SUBSIDIARIES OF COHERUS BIOSCIENCES, INC. Name of Subsidiary Jurisdiction of Organization Surface Oncology, LLC Delaware

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 COHERUS BIOSCIENCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commissio

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update – Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures – – UDENYCA® net revenue increased 62% year-over-y

Exhibit 99.1 Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update – Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures – – UDENYCA® net revenue increased 62% year-over-year – – LOQTORZI® net revenue increased 29% quarter-over-quarter – – UDENYCA divestiture on track with Special Meeting of Shareholders ta

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 COHERUS BIOSCIENCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2025 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 COHERUS BIOSCIENCES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2025 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul

CALCULATION OF FILING FEE TABLE Schedule 14A (Form Type) Coherus BioSciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation

Exhibit 107 CALCULATION OF FILING FEE TABLE Schedule 14A (Form Type) Coherus BioSciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

Exhibit 99.1 2024 Preliminary Revenues and Cash ©2025 Coherus BioSciences 39 2024 Total Year Expected Net Revenues $255M- $260M Cash, Cash Equivalents & Investments Q4 expected net revenues $49M-$54M OBI and strong pricing continue to differentiate t

Exhibit 99.1 2024 Preliminary Revenues and Cash ©2025 Coherus BioSciences 39 2024 Total Year Expected Net Revenues $255M- $260M Cash, Cash Equivalents & Investments Q4 expected net revenues $49M-$54M OBI and strong pricing continue to differentiate the franchise and drive net revenues UDENYCA LOQTORZI Expected sales of $7M-$8M, with consecutive QoQ growth exceeding 20% since launch in Q1 Expected

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 COHERUS BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2024 COHERUS BIOSCIE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2024 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commis

Asset Purchase Agreement, by and between Coherus BioSciences, Inc. and Intas Pharmaceuticals Ltd., dated December 2, 2024.*

EX-2.1 2 tm2429853d2ex2-1.htm EXHIBIT 2.1   Exhibit 2.1       ASSET PURCHASE AGREEMENT   BY AND BETWEEN   COHERUS BIOSCIENCES, INC.,   AND   INTAS PHARMACEUTICALS LTD.   DATED AS OF December 2, 2024             TABLE OF CONTENTS         Page         Article I DEFINITIONS 4     Section 1.1   Definitions 4 Section 1.2   Construction 21         Article II PURCHASE AND SALE 21     Section 2.1   Purcha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

Asset Purchase Agreement, by and between Coherus BioSciences, Inc. and Intas Pharmaceuticals Ltd., dated December 2, 2024.

  Exhibit 2.1       ASSET PURCHASE AGREEMENT   BY AND BETWEEN   COHERUS BIOSCIENCES, INC.,   AND   INTAS PHARMACEUTICALS LTD.   DATED AS OF December 2, 2024             TABLE OF CONTENTS         Page         Article I DEFINITIONS 4     Section 1.1   Definitions 4 Section 1.2   Construction 21         Article II PURCHASE AND SALE 21     Section 2.1   Purchase and Sale of Assets 21 Section 2.2   Exc

Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd. - Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed ce

Exhibit 99.1 Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd. - Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor – - Proceeds to fund development of key combination programs, with LOQTORZI including casdozokitug, a

Press Release of Coherus BioSciences, Inc., dated December 3, 2024

Exhibit 99.1 Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd. - Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI®, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor – - Proceeds to fund development of key combination programs, with LOQTORZI including casdozokitug, a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 COHERUS BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 COHERUS BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2024 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commiss

CHRS / Coherus BioSciences, Inc. / Rubric Capital Management LP - SC 13G Passive Investment

SC 13G 1 tm2427812d5sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Coherus BioSciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 19249H103 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 COHERUS BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 C

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update – Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter–

Exhibit 99.1 Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update – Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter– – UDENYCA labeling and packaging production resuming at third-party contract manufacturing organization – – LOQTORZI® launch progressing to plan, revenues increase 50% quarter-over-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2024 COHERUS BIOSCI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2024 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commi

* * * *

Via EDGAR Transmission September 6, 2024 Division of Corporation Finance Disclosure Review Program United States Securities and Exchange Commission 100 F Street, N.

Amended and Restated 2014 Equity Incentive Award Plan.

EXHIBIT 10.3 COHERUS BIOSCIENCES, INC. AMENDED AND RESTATED 2014 EQUITY INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE The purpose of the Coherus BioSciences, Inc. Amended and Restated 2014 Equity Incentive Award Plan (as it may be amended from time to time, the “Plan”) is to promote the success and enhance the value of Coherus BioSciences, Inc. (the “Company”) by linking the individual interests of the

Coherus BioSciences, Inc. Amended and Restated 2014 Equity Incentive Award Plan.

Exhibit 99.1(a) COHERUS BIOSCIENCES, INC. AMENDED AND RESTATED 2014 EQUITY INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE The purpose of the Coherus BioSciences, Inc. Amended and Restated 2014 Equity Incentive Award Plan (as it may be amended from time to time, the “Plan”) is to promote the success and enhance the value of Coherus BioSciences, Inc. (the “Company”) by linking the individual interests of t

Omnibus Amendment to Transaction Documents dated as of June 25, 2024 among Coherus BioSciences, Inc., Coduet Royalty Holdings, LLC and Ankura Trust Company, LLC.

EXHIBIT 10.4 [***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. EXECUTION VERSION OMNIBUS AMENDMENT TO TRANSACTION DOCUMENTS This OMNIBUS AMENDMENT TO TRANSACTION DOCUMENTS, dated as of June 25, 2024 (this “Omnibus Amendment”), is by and among Coduet Royalty Holdings, LLC, a Delaware limited liability company, as coll

As filed with the Securities and Exchange Commission on August 8, 2024

As filed with the Securities and Exchange Commission on August 8, 2024 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Coherus BioSciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coheru

Exclusive License and Distribution Agreement dated as of June 27, 2024 between Coherus BioSciences, Inc. and Apotex, Inc.

EXHIBIT 10.5 [***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. Execution Version EXCLUSIVE LICENSE AND DISTRIBUTION AGREEMENT (CANADA) This Exclusive License and Distribution Agreement (Canada) (“Agreement”) is entered into on June 27, 2024 (the “Effective Date”) between Coherus BioSciences, Inc., a company organized

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update – Net revenue of $65.0 million in Q2 2024 – – CHS-114 Phase 1 Study Recruitment Continues into Expansion Cohorts in Head and Neck Cancer in Combination wit

Exhibit 99.1 Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update – Net revenue of $65.0 million in Q2 2024 – – CHS-114 Phase 1 Study Recruitment Continues into Expansion Cohorts in Head and Neck Cancer in Combination with LOQTORZI – – Bryan McMichael Appointed as Chief Financial Officer – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, C

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commissio

CHRS / Coherus BioSciences, Inc. / Temasek Holdings (Private) Ltd - SC 13G/A Passive Investment

SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Coherus BioSciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 COHERUS BIOSCIENCES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introductory Note On June 26, 2024, Coherus BioSciences, Inc., a Delaware corporation (“Coherus”), entered into an Asset Purchase Agreement (the “Purchase Agreement”) by and between Coherus and Hong Kong King-Friend Industrial Company Ltd., a Hong Kong corporation (“HKF”). HKF is the parent company of Meitheal Pharmaceutical

Asset Purchase Agreement, by and between Coherus BioSciences, Inc. and Hong Kong King-Friend Industrial Company Ltd., dated as of June 26, 2024

EXHIBIT 2.1 Execution Version [***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. ASSET PURCHASE AGREEMENT BY AND BETWEEN COHERUS BIOSCIENCES, INC. AND HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. DATED AS OF JUNE 26, 2024 US-DOCS\150346962.14 300930969 TABLE OF CONTENTS ‌ Page Article I DEFINITIONS‌4 Section 1.1 Defi

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction – Transaction aligns with Coherus’ strategic focus on oncology –

EXHIBIT 99.1 Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction – Transaction aligns with Coherus’ strategic focus on oncology – REDWOOD CITY, Calif., June 27, 2024 - Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend Industrial Co. Ltd. (HKF) for

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 COHERUS BIOSCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 COHERUS BIOSCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission

Joint Filing Agreement, dated as of May 22, 2024, by and among Temasek, FMPL, TLS and V-Sciences.

EX-99.1 2 d824356dex991.htm EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13G initially filed on August 31, 2017, as amended on February 7, 2020 and May 22, 2024 (the “Schedule 13G”), with respect to the Common Stock, par value $0.0001 per share, of Coherus BioSciences, Inc. is, and any further amendments thereto executed by each of us shal

CHRS / Coherus BioSciences, Inc. / Temasek Holdings (Private) Ltd - SC 13G/A Passive Investment

SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Coherus BioSciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of

Revenue Participation Right Purchase and Sale Agreement dated as of May 8, 2024 among Coherus BioSciences, Inc. and Coduet Royalty Holdings, LLC.

EXHIBIT 10.2 [***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. EXECUTION COPY Revenue Participation Right Purchase and Sale Agreement By and Between Coherus Biosciences, Inc. and Coduet Royalty Holdings, LLC Dated as of May 8, 2024 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.1 Definitions 1 Section 1.2 Cer

Loan Agreement dated as of May 8, 2024 among Coherus BioSciences, Inc., the Guarantors, the Collateral Agent and the Lenders party thereto.

EXHIBIT 10.1 [***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. Execution Version LOAN AGREEMENT Dated as of May 8, 2024 among COHERUS BIOSCIENCES, INC. (as Borrower, and a Credit Party), COHERUS INTERMEDIATE CORP. and INTEKRIN THERAPEUTICS INC. (as additional Credit Parties), THE OTHER GUARANTORS SIGNATORY HERETO OR

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coher

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission F

Amendment No. 2 to the Exclusive License and Commercialization Agreement, as amended, as of March 13, 2024, by and between Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd.

EXHIBIT 10.2 [***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. Amendment No. 2 to Exclusive License and Commercialization Agreement This Amendment No. 2 to the Exclusive License and Commercialization Agreement, as amended (this “Amendment No. 2”), is made and entered into as of March 13, 2024, by and between Shanghai

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 COHERUS BIOSCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission F

Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update – Net revenue of $77.1 million in Q1 2024 – – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty fi

Exhibit 99.1 Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update – Net revenue of $77.1 million in Q1 2024 – – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces $75 million term loan, with debt maturity of May 2029 – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14

As filed with the Securities and Exchange Commission on March 28, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Coherus BioSciences, Inc. (Exact name of registr

Registration No. 333-    As filed with the Securities and Exchange Commission on March 28, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Coherus BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 27-3615821 (State or other jurisdiction of incorporation or organization

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Coherus BioSciences, Inc.

Coherus BioSciences, Inc. Insider Trading Compliance Policy and Procedures, effective February 27, 2023.

EXHIBIT 10.38 COHERUS BIOSCIENCES, INC. INSIDER TRADING COMPLIANCE POLICY AND PROCEDURES Effective February 27, 2023 I. SUMMARY Federal and state laws prohibit trading in the securities of a company while in possession of material non-public information and in breach of a duty of trust or confidence. These laws also prohibit anyone who is aware of material non-public information from providing thi

License Agreement, dated as of December 16, 2020, by and between Surface Oncology, Inc. and GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No. 4) LIMITED.

Exhibit 10.34 CERTAIN IDENTIFIED INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY “[***]”, HAS BEEN EXCLUDED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. LICENSE AGREEMENT THIS LICENSE AGREEMENT (this “Agreement”), is entered into as of December 16, 2020 (the “Effective Date”), by and between Surface Oncology, Inc., a Delawa

Coherus BioSciences, Inc. Clawback Policy, effective December 1, 2023.

EXHIBIT 97.1 COHERUS BIOSCIENCES, INC. (the “Company”) CLAWBACK POLICY Approved and adopted by the Board on December 1, 2023 Introduction The Board of Directors of the Company (the “Board”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company's pay-for-performance

Collaboration Agreement between Novartis Institutes for BioMedical Research, Inc. and Surface Oncology, Inc., dated January 9, 2016, as amended on May 6, 2016, as further amended on July 14, 2017, and as further amended on September 18, 2017.

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”.

Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350.

Exhibit 32.1 CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officers of Coherus BioSciences, Inc. (the “Registrant”) certify that the Registra

Exclusive Product License Agreement, dated March 23, 2021, by and between Vaccinex, Inc. and Surface Oncology, Inc.

Exhibit 10.40 CERTAIN IDENTIFIED INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY “[***]”, HAS BEEN EXCLUDED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) THE TYPE THAT SURFACE ONCOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL. Exclusive Product License Agreement This Exclusive Product License Agreement (this “Agreement”) is made and entered into as of this 23rd day of March, 2021 (the “Effective Da

Sixth Amendment, effective October 24, 2023, by and between Hudson 333 Twin Dolphin Plaza, LLC and Coherus BioSciences, Inc.

EXHIBIT 10.36 [***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. SIXTH AMENDMENT THIS SIXTH AMENDMENT (this “Amendment”) is made and entered into as of October 24, 2023, by and between HUDSON 333 TWIN DOLPHIN PLAZA, LLC, a Delaware limited liability company (“Landlord”), and COHERUS BIOSCIENCES, INC., a Delaware corpo

Amendment No. 4 to the Collaboration Agreement between Novartis Institutes for BioMedical Research, Inc. and Surface Oncology, Inc., dated October 9, 2018.

Exhibit 10.33 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. CONFIDENTIAL FOURTH AMENDMENT TO COLLA

First Amended and Restated Development and Option Agreement between Adimab, LLC and Surface Oncology, Inc., dated October 3, 2018.

Exhibit 10.31 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Execution Copy CONFIDENTIAL FIRST AMEN

Subsidiaries of Coherus BioSciences, Inc.

EXHIBIT 21.1 SIGNIFICANT SUBSIDIARIES OF COHERUS BIOSCIENCES, INC. Name of Subsidiary Jurisdiction of Organization Surface Oncology, LLC Delaware

Letter Agreement between Coherus BioSciences, Inc. and McDavid Stilwell, dated as of December 11, 2023.

[***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update – Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth

Exhibit 99.1 Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update – Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – – CIMERLI® net sales of $52.4 million in the fourth quarter and $125.4 million in FY 2023 – – LO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 COHERUS BIOSCIENCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commissio

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introductory Note As previously announced, on January 19, 2024, Coherus BioSciences, Inc., a Delaware corporation (“Coherus”), entered into a Purchase and Sale Agreement (the “Purchase Agreement”) by and between Coherus and Sandoz Inc., a Delaware corporation (“Purchaser”). On March 1, 2024, Coherus completed the previously

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2024 COHERUS BIOSCIENCES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2024 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission

Coherus Completes Divestiture of Ophthalmology Franchise – Upfront cash payment of $170 million strengthens capital structure – – Transaction solidifies Coherus’ strategic focus in oncology –

Exhibit 99.1 Coherus Completes Divestiture of Ophthalmology Franchise – Upfront cash payment of $170 million strengthens capital structure – – Transaction solidifies Coherus’ strategic focus in oncology – REDWOOD CITY, Calif., March 4, 2024 - Coherus BioSciences, Inc. (NASDAQ: CHRS) today announced the completion of the previously announced divestiture of its CIMERLI® (ranibizumab-eqrn) ophthalmol

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 COHERUS BIOSCIE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commis

CHRS / Coherus BioSciences, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Coherus BioSciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (the “Shares”) (Title of Class of Securities) 19249H10

CHRS / Coherus BioSciences, Inc. / ALLIANCEBERNSTEIN L.P. - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Coherus Biosciences Inc (Name of Issuer) Common Stock (Title of Class of Securities) 19249H103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi

CHRS / Coherus BioSciences, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0641-coherusbiosciencesinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Coherus Biosciences Inc Title of Class of Securities: Common Stock CUSIP Number: 19249H103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2024 COHERUS BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2024 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commiss

Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP - Estimated balance of $75 million upon $175 million paydown of principal projected in Q2 2024 - - Revenue covenant reduced to $125 million - - Term loan annual interest expense projected

Exhibit 99.1 Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP - Estimated balance of $75 million upon $175 million paydown of principal projected in Q2 2024 - - Revenue covenant reduced to $125 million - - Term loan annual interest expense projected to be reduced by ~70% - REDWOOD CITY, Calif., February 5, 2024 - Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced it

Consent, Partial Release and Third Amendment to Loan Agreement dated as of February 5, 2024 among Coherus BioSciences, Inc., Biopharma Credit PLC, BPCR Limited Partnership and Biopharma Credit Investments V (MASTER) LP

EXHIBIT 10.1 Execution Version [***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. CONSENT, PARTIAL RELEASE AND THIRD AMENDMENT TO LOAN AGREEMENT This Consent, Partial Release, Third Amendment to Loan Agreement (this “Amendment”), dated as of February 5, 2024 (the “Third Amendment Effective Date”), is entered into by a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2024 COHERUS BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2024 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commiss

Purchase and Sale Agreement, by and between Coherus BioSciences, Inc. and Sandoz Inc., dated January 19, 2024

EX-2.1 Exhibit 2.1 [***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. Execution Version PURCHASE AND SALE AGREEMENT between COHERUS BIOSCIENCES, INC., as Seller, and SANDOZ INC., as Buyer Dated as of January 19, 2024 THIS DOCUMENT IS FOR DISCUSSION PURPOSES ONLY AND SHALL NOT GIVE RISE TO ANY DUTY TO NEGOTIATE, CREATE

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal – Transaction aligns to Coherus’ strategic focus on oncology – – Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time –

EX-99.1 Exhibit 99.1 Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal – Transaction aligns to Coherus’ strategic focus on oncology – – Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time – REDWOOD CITY, Calif., January 22, 2024 — Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced it has entered into an ag

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2024 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2024 COHERUS BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2024 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commiss

Exhibit 99.1 © 2024 Coherus BioSciences. 2023 Revenue Growth Quarter over quarter sales growth from Q1 through Q4 6 2023 Net Revenues ($255 - $260 million) achieved upper end of guidance range Q4 revenues >$90M CIMERLI – Quarter-over-quarter revenue

Exhibit 99.1 © 2024 Coherus BioSciences. 2023 Revenue Growth Quarter over quarter sales growth from Q1 through Q4 6 2023 Net Revenues ($255 - $260 million) achieved upper end of guidance range Q4 revenues >$90M CIMERLI – Quarter-over-quarter revenue growth after Q-Code April 2023 UDENYCA – Quarter-over-quarter net revenue growth Strong ASP to support Q1 2024 OBI launch Three presentations provide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2023 COHERUS BIOSCIE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 26, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2023 COHERUS BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commiss

CHRS / Coherus Biosciences Inc / JPMORGAN CHASE & CO - FILING COHERUS BIOSCIENCES, INC. Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 03)* Coherus BioSciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 19249H103 (CUSIP Number) November 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 COHERUS BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 COHERUS BIOSCIE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2023 COHERUS BIOSC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 C

Settlement and License Agreement among Coherus BioSciences, Inc., AbbVie Inc. and AbbVie Biotechnology Ltd dated January 24, 2019.

EXHIBIT 10.1 [***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. SETTLEMENT AND LICENSE AGREEMENT THIS SETTLEMENT AND LICENSE AGREEMENT ("Agreement"), effective January 24, 2019 ("Effective Date"), is entered into by and among AbbVie Inc., a corporation organized and existing under the laws of Delaware, having its corp

Amendment No. 2 to Sales Agreement between Coherus BioSciences, Inc. and Cowen and Company, LLC dated September 11, 2023.

EXHIBIT 10.2 Coherus BioSciences, Inc. Common Stock AMENDMENT NO. 2 TO SALES AGREEMENT September 11, 2023 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Reference is made to the Sales Agreement, dated November 8, 2022, as amended by that certain Amendment No. 1 to Sales Agreement, dated May 15, 2023 (together, the “Agreement”), by and between Coherus BioScienc

Report of Independent Registered Public Accounting Firm

Exhibit 99.1 Report of Independent Registered Public Accounting Firm To the Board of Directors and Stockholders of Surface Oncology, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Surface Oncology, Inc. and its subsidiary (the “Company”) as of December 31, 2022 and 2021, and the related consolidated statements of operations and comprehensiv

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information has been presented to illustrate the estimated effect of the acquisition by Coherus BioSciences, Inc. (“Coherus”), a Delaware corporation, Crimson Merger Sub I, Inc., a direct, wholly owned subsidiary of Coherus (“Merger Sub I”), a Delaware corporatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 COHERUS BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commiss

Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights – Net revenue rose 27% from prior quarter to $74.6 million – – CIMERLI® net sales increased 50% to $40 million compared to prior quarter – – LOQTORZI™ now approv

Exhibit 99.1 Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights – Net revenue rose 27% from prior quarter to $74.6 million – – CIMERLI® net sales increased 50% to $40 million compared to prior quarter – – LOQTORZI™ now approved with launch planned for the first quarter of 2024 – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., November

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2023 COHERUS BIOSC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2023 COHERUS BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commiss

Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) – LOQTORZI is the first and only FDA-approved treatment for NPC – – Indicated in

Exhibit 99.1 Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) – LOQTORZI is the first and only FDA-approved treatment for NPC – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with disease progression on or after platinum conta

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 COHERUS BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commiss

Unregistered Sales of Equity Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commissi

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commi

Up to $78,407,207 Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-268252 PROSPECTUS Up to $78,407,207 Common Stock We previously entered into a sales agreement with Cowen and Company, LLC, or TD Cowen, dated as of November 8, 2022 and as amended on May 15, 2023 and September 11, 2023, relating to shares of our common stock, $0.0001 par value per share, offered by this prospectus supplement

Coherus Completes Surface Oncology Acquisition – Clinical-stage product candidates, casdozokitug and CHS-114, significantly advance next-generation immuno-oncology portfolio focused on the tumor microenvironment – – I-O combinations will potentially

Exhibit 99.1 Coherus Completes Surface Oncology Acquisition – Clinical-stage product candidates, casdozokitug and CHS-114, significantly advance next-generation immuno-oncology portfolio focused on the tumor microenvironment – – I-O combinations will potentially expand toripalimab opportunity into large indications with high unmet need – REDWOOD CITY, Calif., September 8, 2023 - Coherus BioScience

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2023 COHERUS BIOSCIE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coheru

Amendment No. 1 to Sales Agreement between Coherus BioSciences, Inc. and Cowen and Company, LLC, dated May 15, 2023.

EXHIBIT 10.1 Coherus BioSciences, Inc. Common Stock AMENDMENT NO. 1 TO SALES AGREEMENT May 15, 2023 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Reference is made to the Sales Agreement, dated November 8, 2022 (the “Agreement”), by and between Coherus BioSciences, Inc., a Delaware corporation (the “Company”), and Cowen and Company, LLC (“Cowen”). The Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 COHERUS BIOSCIENCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commissio

Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights – Net revenue rose 81% from prior quarter to $58.7 million – – CIMERLI® net sales quadrupled to $26.7 million compared to prior quarter – – UDENYCA® autoinjecto

Exhibit 99.1 Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights – Net revenue rose 81% from prior quarter to $58.7 million – – CIMERLI® net sales quadrupled to $26.7 million compared to prior quarter – – UDENYCA® autoinjector launched in late May, and YUSIMRY™ launched in July – – Planned merger with Surface Oncology expected to significantly advance next-gen

MERGER PROPOSAL—YOUR VOTE IS VERY IMPORTANT

424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-273179 MERGER PROPOSAL—YOUR VOTE IS VERY IMPORTANT Dear Surface Oncology, Inc. Stockholders: On June 15, 2023, Surface Oncology, Inc. (“Surface”) entered into an Agreement and Plan of Merger (the “Merger Agreement”), with Coherus BioSciences, Inc. (“Coherus”), Crimson Merger Sub I, Inc., a direct, wholly owned subsidiary

Form of Proxy Card for Special Meeting of Surface Oncology, Inc.

EX-99.2 Exhibit 99.2 SURFACE ONCOLOGY, INC. 50 HAMPSHIRE STREET, 8TH FLOOR CAMBRIDGE, MA 02139 SCAN TO VIEW MATERIALS & VOTE VOTE BY INTERNET Before The Meeting - Go to www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information. Vote by 11:59 p.m. Eastern Time on September 6, 2023. Have your proxy card in hand whe

As filed with the U.S. Securities and Exchange Commission on July 24, 2023

S-4/A Table of Contents As filed with the U.S. Securities and Exchange Commission on July 24, 2023 Registration No. 333-273179 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Coherus BioSciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2836 27-3615821 (State of I

Power of Attorney for Michael Ryan

EX-24.2 Exhibit 24.2 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Dennis M. Lanfear and McDavid Stilwell, and each of them singly (with full power to each of them to act alone), as his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them, for him and in his name, place and stea

Coherus BioSciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065

Coherus BioSciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065 July 24, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: Coherus BioSciences, Inc. Registration Statement on Form S-4 (File No. 333-273179) Ladies and Gentlemen: In accordance with Rule 461 of the General Rules and Regulation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2023 COHERUS BIOSCIENCES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission

Calculation of Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) Coherus BioSciences, Inc.

Power of Attorney (included on the signature page of the initial filing of this registration statement)

S-4 Table of Contents As filed with the U.S. Securities and Exchange Commission on July 7, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Coherus BioSciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2836 27-3615821 (State of Incorporation) (Primary Stand

Consent of Financial Advisor to Surface

EX-99.1 Exhibit 99.1 Wedbush Securities Inc. 600 Montgomery Street 29th Floor San Francisco, CA 94111 July 7, 2023 Board of Directors Surface Oncology, Inc. 50 Hampshire Street, 8th Floor Cambridge, MA 02139 We hereby consent to the inclusion of our opinion letter, dated June 15, 2023, to the Board of Directors of Surface Oncology, Inc. (the “Company”), as Annex C to, and the references to such op

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 COHERUS BIOSCIENCES

425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commis

2

425 Filed by Coherus BioSciences, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Surface Oncology, Inc. (Subject Company Commission File No.: 001-38459) This filing relates to the proposed merger involving Coherus BioSciences, Inc., a Delaware corporation (the “Company”), Crimson Merger

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 SURFACE ONCOLOGY, I

425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 SURFACE ONCOLOGY, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38459 46-5543980 (State or Other Jurisdiction of Incorporation) (Commissio

Coherus to Acquire Surface Oncology – Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – – Acquisition s

EX-99.1 EXHIBIT 99.1 Coherus to Acquire Surface Oncology – Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – – Acquisition significantly advances Coherus’ I-O pipeline with anti-IL-27 and anti-CCR8 clinical programs– – Stock for stock transaction valued

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission

Agreement and Plan of Merger, by and among Coherus BioSciences, Inc., Crimson Merger Sub I, Inc., Crimson Merger Sub II, LLC and Surface Oncology, Inc., dated June 15, 2023 (Form of CVR Agreement included as Exhibit A thereto)

EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among COHERUS BIOSCIENCES, INC., CRIMSON MERGER SUB I, INC., CRIMSON MERGER SUB II, LLC and SURFACE ONCOLOGY, INC. Dated as of June 15, 2023 TABLE OF CONTENTS Page ARTICLE I THE MERGERS 2 Section 1.1 The Mergers 2 Section 1.2 Closing 2 Section 1.3 Effective Time 3 Section 1.4 Effects of the Mergers 3 Section 1.5 Certificate of Incor

Filed by Coherus BioSciences, Inc.

425 Filed by Coherus BioSciences, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Surface Oncology, Inc. (Subject Company Commission File No.: 001-38459) This filing relates to the proposed merger involving Coherus BioSciences, Inc., a Delaware corporation (the “Company”), Crimson Merger

Filed by Coherus BioSciences, Inc.

425 Filed by Coherus BioSciences, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Surface Oncology, Inc. (Subject Company Commission File No.: 001-38459) This filing relates to the proposed merger involving Coherus BioSciences, Inc., a Delaware corporation (the “Company”), Crimson Merger

Filed by Coherus BioSciences, Inc.

425 Filed by Coherus BioSciences, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Surface Oncology, Inc. (Subject Company Commission File No.: 001-38459) This filing relates to the proposed merger involving Coherus BioSciences, Inc., a Delaware corporation (the “Company”), Crimson Merger

Filed by Coherus BioSciences, Inc.

425 Filed by Coherus BioSciences, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Surface Oncology, Inc. (Subject Company Commission File No.: 001-38459) This filing relates to the proposed merger involving Coherus BioSciences, Inc., a Delaware corporation (the “Company”), Crimson Merger

Filed by Coherus BioSciences, Inc.

425 Filed by Coherus BioSciences, Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Surface Oncology, Inc. (Subject Company Commission File No.: 001-38459) This filing relates to the proposed merger involving Coherus BioSciences, Inc., a Delaware corporation (the “Company”), Crimson Merger

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 COHERUS BIOSCIENCES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 COHERUS BIOSCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 COHERUS BIOSCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission

CHRS / Coherus Biosciences Inc / CITADEL ADVISORS LLC - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Coherus Biosciences, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (the “Shares”) (Title of Class of Securities) 19249H103

JOINT FILING AGREEMENT

EX-99.1 2 tm2316304d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Coherus Biosciences, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 193

Underwriting Agreement, dated as of May 16, 2023, among Coherus BioSciences, Inc. and J.P. Morgan Securities LLC and Citigroup Global Markets Inc., as representatives of the several underwriters named therein

Exhibit 1.1 COHERUS BIOSCIENCES, INC. 11,764,706 Shares of Common Stock Underwriting Agreement May 16, 2023 J.P. Morgan Securities LLC Citigroup Global Markets Inc. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 Ladie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 COHERUS BIOSCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission

Coherus BioSciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065 (650) 649-3530

424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No.

Coherus BioSciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065 (650) 649-3530

424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 COHERUS BIOSCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission

Second Amendment and Waiver to Loan Agreement dated as of February 6, 2023, among Coherus BioSciences, Inc., the Collateral Agent and the Lenders party thereto.

EXHIBIT 10.1 [***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. Execution Version SECOND AMENDMENT AND WAIVER This SECOND AMENDMENT AND WAIVER (this “Amendment and Waiver”), dated and effective as of February 6, 2023 (the “Second Amendment Effective Date”), is made by and among COHERUS BIOSCIENCES, INC., a Delaware co

Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights – UDENYCA® autoinjector approved and ready for May 2023 launch – – CIMERLI® product-specific Q-code now facilitating electronic reimbursement following April 1 a

Exhibit 99.1 Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights – UDENYCA® autoinjector approved and ready for May 2023 launch – – CIMERLI® product-specific Q-code now facilitating electronic reimbursement following April 1 activation – – FDA inspection of toripalimab manufacturing site scheduled for May 2023 – – Toripalimab launch anticipated in Q3 2023, if a

Letter Agreement between Coherus BioSciences, Inc. and Vladimir Vexler, dated as of March 27, 2023.

[***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coher

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 COHERUS BIOSCIENCES,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission F

Executive Change in Control and Severance Plan, effective January 1, 2023.

EXHIBIT 10.2 COHERUS BIOSCIENCES, INC. EXECUTIVE CHANGE IN CONTROL AND SEVERANCE PLAN (AND SUMMARY PLAN DESCRIPTION) EFFECTIVE JANUARY 1, 2023 This Coherus BioSciences, Inc. Executive Change in Control and Severance Plan (this “Plan”) was originally established effective as of April 5, 2017 and is hereby amended and restated effective January 1, 2023 (the “Effective Date”). The purpose of this Pla

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ◻ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC

Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results – Net product sales of $45.4 million in the fourth quarter 2022 and $211.0 million in FY 2022 – – FDA is planning the toripalimab manufacturing site inspection in Q2 2023 – – UDENY

Exhibit 99.1 Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results – Net product sales of $45.4 million in the fourth quarter 2022 and $211.0 million in FY 2022 – – FDA is planning the toripalimab manufacturing site inspection in Q2 2023 – – UDENYCA® autoinjector approved by FDA; UDENYCA® on-body injector under review by FDA – – Planning underway for potential 2023 commercial launc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 COHERUS BIOSCIENCES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission

License Agreement, dated June 22, 2022, among Coherus BioSciences, Inc., Bioeq AG and Genentech Inc.

EXHIBIT 10.25 [***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. EXECUTION COPY LICENSE AGREEMENT This License Agreement (the “License Agreement”) is made and entered into this 22nd day of June, 2022 (the “Effective Date”), by and between Genentech, Inc., a corporation organized under the laws of Delaware (“Genentech”

CHRS / Coherus Biosciences Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

SC 13G/A 1 d444672dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Coherus BioSciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 19249H 103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statemen

AGREEMENT

EX-99.1 2 d444672dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2

CHRS / Coherus Biosciences Inc / ALLIANCEBERNSTEIN L.P. - SEC SCHEDULE 13G Passive Investment

SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Coherus Biosciences Inc (Name of Issuer) Common Stock (Title of Class of Securities) 19249H103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo

CHRS / Coherus Biosciences Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Coherus Biosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 19249H103 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is fil

CHRS / Coherus Biosciences Inc / JPMORGAN CHASE & CO - FILING COHERUS BIOSCIENCES, INC. Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* Coherus BioSciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 19249H103 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

As filed with the Securities and Exchange Commission on January 18, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Coherus BioSciences, Inc. (Exact name of regis

Registration No. 333- As filed with the Securities and Exchange Commission on January 18, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Coherus BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 27-3615821 (State or other jurisdiction of incorporation or organization)

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Coherus BioSciences, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 COHERUS BIOSCIENC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commissi

Up to $150,000,000 Common Stock

424B5 1 tm2229489-3424b5.htm 424B5 TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-268252 PROSPECTUS Up to $150,000,000 Common Stock We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to shares of our common stock, $0.0001 par value per share, offered by this prospectus supplement and the accompanying prospectus. In accordance with the

Coherus BioSciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065

CORRESP 1 filename1.htm Coherus BioSciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065 November 15, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: Coherus BioSciences, Inc. Registration Statement on Form S-3 (File No. 333-268252) Ladies and Gentlemen: In accordance with Rule 461 of the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 COHERUS BIOSCIEN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commiss

Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update – UDENYCA® net sales of $45.4 million in the third quarter 2022 – – CIMERLI™ launched in the United States on October 3rd – – Planning underway for 2023 commercial la

Exhibit 99.1 Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update – UDENYCA® net sales of $45.4 million in the third quarter 2022 – – CIMERLI™ launched in the United States on October 3rd – – Planning underway for 2023 commercial launches of toripalimab, YUSIMRY™ and UDENYCA® OBI – – Conference call today at 5 p.m. ET – REDWOOD CITY, Calif., November 8, 2022 – Coheru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 C

Sales Agreement, dated as of November 8, 2022, by and between the registrant and Cowen and Company, LLC.

EX-1.2 2 tm2229489d1ex1-2.htm EXHIBIT 1.2 Exhibit 1.2 COHERUS BIOSCIENCES, INC. $150,000,000 COMMON STOCK SALES AGREEMENT November 8, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Coherus BioSciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1.        Issuan

Form of Indenture.

Exhibit 4.5 Coherus BioSciences, Inc. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 6 Section 2.1. Issuable in Series 6 Section 2.2. Establ

As filed with the Securities and Exchange Commission on November 8, 2022

As filed with the Securities and Exchange Commission on November 8, 2022 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Coherus BioSciences, Inc.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2022 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commissio

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2022 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commis

Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update – Commercial launch of CIMERLI™ planned for early October 2022 – – PDUFA date for toripalimab BLA is December 23, 2022 – – Commercial preparation underway for planne

Exhibit 99.1 ? ? Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update ? ? Commercial launch of CIMERLI? planned for early October 2022 ? ? PDUFA date for toripalimab BLA is December 23, 2022 ? ? Commercial preparation underway for planned July 2023 launch of YUSIMRY? ? ? UDENYCA? delivers 2nd quarter 2022 net sales of $60.1 million ? ? Conference call today at 5 p.m

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): August 4, 2022 ? ? COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) ? ? Delaware 001-36721 27-3615821 (State or other jurisdiction of inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

First Amendment to Loan Agreement dated as of April 7, 2022, among Coherus BioSciences, Inc., the Collateral Agent and the Lenders party thereto.

EXHIBIT 10.1 ? ? [***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. ? FIRST AMENDMENT TO LOAN AGREEMENT This FIRST AMENDMENT TO LOAN AGREEMENT (this ?Amendment?), dated and effective as of April 7, 2022 (the ?Effective Date?), is made by and among COHERUS BIOSCIENCES, INC., a Delaware corporation (as ?Borrower? and a

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2022 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commission F

Letter Agreement, dated February 9, 2022, between Coherus BioSciences, Inc. and Shanghai Junshi Biosciences, Co., Ltd.

EXHIBIT 10.1 ? [***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. ? Execution Version Confidential ? ? ? ? February 9, 2022 ? SHANGHAI JUNSHI BIOSCIENCES CO., LTD. Level 13, Building 2, Nos. 36 and 58, Hai Qu Road, Shanghai, China 201203 Attention: CEO CC: Board Secretary, Securities Department ? ? Re: Extension of Ri

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): May 3, 2022 ? ? COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) ? ? Delaware 001-36721 27-3615821 (State or other jurisdiction of incorp

Coherus BioSciences Reports First Quarter 2022 Results – CIMERLI™ BLA review progressing toward August 2022 action date – – Toripalimab BLA resubmission expected by mid-summer – – UDENYCA® delivers 1st quarter 2022 net sales of $60.1 million – – 2022

Exhibit 99.1 ? ? Coherus BioSciences Reports First Quarter 2022 Results ? ? CIMERLI? BLA review progressing toward August 2022 action date ? ? Toripalimab BLA resubmission expected by mid-summer ? ? UDENYCA? delivers 1st quarter 2022 net sales of $60.1 million ? ? 2022 R&D and SG&A expense guidance reduced by $20 million ? ? Conference call today at 4:30 p.m. ET ? ? REDWOOD CITY, Calif., May 5, 20

Notice of Successor Trustee to Indenture dated February 7, 2022.

EXHIBIT 4.5 ? [***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. ? ? From: [***] Sent: 07 February 2022 11:48 AM To: [***]; [***] Subject: US Bank Trustee Succession ? This message was sent from outside Coherus BioSciences. Proceed with caution. ? Hi [***] and [***], ? As you may have been previously notified, U.S. Ba

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

VIA EDGAR

CORRESP 1 filename1.htm VIA EDGAR April 20, 2022 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ibolya Ignat and Angela Connell Division of Corporation Finance Office of Life Sciences RE: Coherus BioSciences, Inc. Form 10-K for Fiscal Year Ended December 31, 2020 Filed February 25, 2021 Form 8-K furnished November 8,

The information specifically incorporated by reference into our Annual Report on Form 10-K from our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 4, 2022.

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? ? Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commissio

Filing Fee Table

Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Coherus BioSciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock,

As filed with the Securities and Exchange Commission on February 23, 2022

As filed with the Securities and Exchange Commission on February 23, 2022 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Letter Agreement, dated January 9, 2022, between Coherus BioSciences, Inc. and Shanghai Junshi Biosciences, Co., Ltd.

EX-10.32 2 chrs-20211231xex10d32.htm EX-10.32 EXHIBIT 10.32 [***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. [Coherus Letterhead] January 9, 2022 SHANGHAI JUNSHI BIOSCIENCES CO., LTD. Level 13, Building 2, Nos. 36 and 58, Hai Qu Road, Shanghai, China 201203 Attention: CEO Via Email: [***] CC: Board Secretary, Securi

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 8-K ? ? CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): February 17, 2022 ? ? COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) ? ? Delaware 001-36721 27-3615821 (State or other jurisdiction of

Coherus BioSciences Reports Fourth Quarter and Full Year 2021 Results – YUSIMRY™ (adalimumab-aqvh), Coherus’ second product, approved by FDA on December 17, 2021 – – BLAs under FDA review for PD-1 inhibitor toripalimab and CIMERLI™ (ranibizumab-ranq)

Exhibit 99.1 ? ? Coherus BioSciences Reports Fourth Quarter and Full Year 2021 Results ? ? YUSIMRY? (adalimumab-aqvh), Coherus? second product, approved by FDA on December 17, 2021 ? ? BLAs under FDA review for PD-1 inhibitor toripalimab and CIMERLI? (ranibizumab-ranq) ? ? New FDA filings expected in 2022 for UDENYCA? on-body injector and additional toripalimab indications ? ? UDENYCA? delivered n

CHRS / Coherus Biosciences Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Coherus BioSciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 19249H 103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa

AGREEMENT

EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them.

CHRS / Coherus Biosciences Inc / ALLIANCEBERNSTEIN L.P. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Coherus Biosciences Inc (Name of Issuer) Common Stock (Title of Class of Securities) 19249H103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi

CHRS / Coherus Biosciences Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Coherus Biosciences Inc. Title of Class of Securities: Common Stock CUSIP Number: 19249H103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fil

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2022 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commiss

Power of Attorney (included in the signature page to this registration statement).

Registration No. 333- As filed with the Securities and Exchange Commission on January 12, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Coherus BioSciences, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 27-3615821 (State or other jurisdiction of incorporation or organization)

Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody

Exhibit 99.1 Coherus and Junshi Biosciences Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody ? Coherus and Junshi Biosciences plan to evaluate the toripalimab + JS006 combination in clinical trials in multiple tumor types ? Combinations of PD-1 + TIGIT inhibitors have potential to expand checkpoint inhibitor utilization to new tumors and lines of therapy REDWOOD CITY, Calif.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2022 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commissi

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commissi

Coherus BioSciences Secures Credit Financing with Pharmakon Advisors Balance sheet strengthened to support commercial launches of as many as five new products in 2022 and 2023

EXHIBIT 99.1 Coherus BioSciences Secures Credit Financing with Pharmakon Advisors Balance sheet strengthened to support commercial launches of as many as five new products in 2022 and 2023 REDWOOD CITY, Calif., Jan. 7, 2022 (GLOBE NEWSWIRE) ? Coherus BioSciences, Inc. (Coherus or the Company) (Nasdaq: CHRS) today announced that it has entered into a loan agreement with investment funds managed by

CHRS / Coherus Biosciences Inc / JPMORGAN CHASE & CO - FILING COHERUS BIOSCIENCES, INC. Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Coherus BioSciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 19249H103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

Loan Agreement dated as of January 5, 2022 among Coherus BioSciences, Inc., the Guarantors, the Collateral Agent and the Lenders party thereto.

EXHIBIT 10.1 [***] Certain information in this exhibit has been omitted because it is permitted to be omitted by applicable regulatory guidance. Execution Version LOAN AGREEMENT Dated as of January 5, 2022 among COHERUS BIOSCIENCES, INC. (as Borrower, and a Credit Party), COHERUS INTERMEDIATE CORP. and INTEKRIN THERAPEUTICS INC. (as additional Credit Parties), THE OTHER GUARANTORS SIGNATORY HERETO

VIA EDGAR

VIA EDGAR December 30, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2021 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commiss

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 COHERUS BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-36721 27-3615821 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.